Already have an account?


Login with an existing Projects In Knowledge account
New to Projects In Knowledge?


Register today to customize your experience.
Log In
Don't have an account yet? Click here to register



Register for Free
Already have an account? Click here to log in



Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.



Forgot Password

Please Enter your email address.




  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy
www.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

Listserves
When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com.

Revision date: This policy was last updated on September 30, 2003.


            
Rated a Top 10 free iPhone app by iMedicalApps
 
HCV Care & Guidance
Practical Education and Resources
Table of Contents  |  CME/CE Information  | Technical Requirements  | Login
  /2037/iPhoneAd/2037iPhoneAd.gif [true]
Chapter 1
Getting Ready for Direct-Acting Antiviral (DAA) Therapy

Chapter 2
What You Need to Know About the New Direct-Acting Antiviral (DAA) Regimens

Chapter 3
Hematologic Adverse Effects

Chapter 4
Dermatologic Adverse Effects

Chapter 5
Gastrointestinal Adverse Effects

Chapter 6
Neuropsychiatric Adverse Effects

Chapter 7
Understanding Drug-Drug Interactions in this New Triple-Therapy Era

Chapter 8
Treating HCV in Special Populations

Chapter 9
Predictors of Response

Chapter 10
Treating Hepatitis C in Patients with Cirrhosis

Chapter 11
Anti-Hepatitis C Triple Therapy Update


HCV Care & Guidance HCV Care & Guidance PDF Print PDF Print
HCV Care & Guidance

iPhone App



 
Table of Contents

Chapter 11 - Anti-Hepatitis C Triple Therapy Update

Since the approval of boceprevir and telaprevir triple therapy in 2011, studies in real-life clinical settings as well as retrospective reviews of phase III data have been undertaken to better understand how to optimize success with these first-generation protease inhibitors. Join Sherilyn C. Brinkley, MSN, CRNP, for this e-handbook chapter, in which she highlights important recent data and label updates for boceprevir and telaprevir triple therapy. "Anti-Hepatitis C Triple Therapy Update,"€ is part of the HCV Care and Guidance: Practical Education and Resources for Nurse Practitioners and Physician Assistants program.
Go to Activity
top
 


Chapter 10 - Treating Hepatitis C in Patients with Cirrhosis

Boceprevir and telaprevir triple therapies offer an improved opportunity for sustained virologic response (SVR) in patients with HCV-related compensated cirrhosis. SVR rates are significantly higher compared with traditional combination therapy in treatment-naive as well as treatment-experienced patients, particularly those who were prior relapsers. In this e-handbook chapter, Patrick M. Horne, BSN, MSN, reviews the importance of diagnosing cirrhosis prior to starting anti-HCV therapy and highlights efficacy and safety data, as well as on-treatment monitoring tips. “Treating Hepatitis C in Patients with Cirrhosis,” is part of the HCV Care and Guidance: Practical Education and Resources for Nurse Practitioners and Physician Assistants program.
Go to Activity
top
 


Chapter 9 - Predictors of Response

Do you know what factors predict response with the new boceprevir and telaprevir triple therapies for genotype 1 chronic hepatitis C? In this e-handbook chapter, using text and numerous graphics, Cheryl D. Levine, PhD, FNP, gives you an overview of how factors such as IL28B genotype, on-treatment response, fibrosis, and prior response to peginterferon/ribavirin, will impact your patients'€™ chances of achieving a sustained virologic response. "€œPredictors of Response," is part of the HCV Care and Guidance: Practical Education and Resources program.
Go to Activity
top
 


Chapter 8 - Treating HCV in Special Populations

Historically, special population groups have been challenging to treat for chronic hepatitis C due to low response rate, comorbidities, poor adherence, and/or drug-drug interactions. In this e-handbook chapter, Sherilyn C. Brinkley, MSN, CRNP, focuses on anti-HCV triple therapy in special populations, including black patients, cirrhotic patients, HIV/HCV-coinfected patients, and patients who are active or inactive substance abusers. Brinkley gives you background for each population group and strategies for successful treatment. "€œTreating Hepatitis C in Special Populations" is part of the HCV Care and Guidance: Practical Education and Resources for Nurse Practitioners and Physician Assistants program.
Go to Activity
top
 


Chapter 7 - Understanding Drug-Drug Interactions in this New Triple-Therapy Era

Do you know how to proceed when your HCV-infected patient is scheduled to start taking boceprevir triple therapy but is also taking digoxin? Do you know if a person taking telaprevir triple therapy can also take St. John's wort? In this e-handbook chapter, Tiffany A. Taskaya, PA-C, CCRC, reviews the mechanisms of drug-drug interactions and shows you how to predict and prevent interactions between the anti-HCV protease inhibitors and common drugs and drug classes. "Understanding Drug-Drug Interactions in This New Triple-Therapy Era" is part of the HCV Care & Guidance: Practical Education and Resources program.
Go to Activity
top
 


Chapter 6 - Neuropsychiatric Adverse Effects

Depression, irritability, and anxiety are common in HCV patients receiving peginterferon/ribavirin treatment. The addition of direct-acting antiviral (DAA) therapy to peginterferon/ribavirin does not appear to further increase the incidence of these neuropsychiatric events, but drug-drug interactions limit the treatment options for depression and anxiety. In the sixth chapter of this eHandbook, HCV Care and Guidance: Practical Education and Resources for Nurse Practitioners and Physician Assistants, Jill Y. Chang, PA-C outlines management strategies for these adverse effects that may help improve patient outcomes.
Go to Activity
top
 


Chapter 5 - Gastrointestinal Adverse Effects

What should you do when a patient on direct-acting antiviral (DAA) therapy for chronic hepatitis C calls the clinic and reports nausea and vomiting? Or when a patient complains of a metallic taste in the mouth? In this chapter, Cheryl D. Levine, PhD, FNP reviews the most common gastrointestinal adverse effects associated with DAA therapy and makes recommendations on how to manage them when they occur in your patients. "Gastrointestinal Adverse Effects" is the fifth chapter in the e-Handbook in the HCV Care and Guidance: Practical Education and Resources for Nurse Practitioners and Physician Assistants program.
Go to Activity
top
 


Chapter 4 - Dermatologic Adverse Effects

Rash is a common reason for discontinuation of anti-HCV therapy. In this chapter, Jill Y. Chang, PA-C reviews the incidence and severity of rash associated with direct-acting antiviral (DAA) triple therapy and outlines a management strategy, so that you can keep more patients on therapy longer. "Dermatologic Adverse Effects"€ is the fourth chapter in the e-Handbook in the HCV Care and Guidance: Practical Education and Resources for Nurse Practitioners and Physician Assistants program.
Go to Activity
top
 


Chapter 3 - Hematologic Adverse Effects

Anemia is a common adverse effect of peginterferon/ribavirin therapy for chronic hepatitis C. The addition of a newly approved protease inhibitor, boceprevir or telaprevir, allows improved sustained virologic response rates but increases the risk and magnitude of anemia. In Chapter 3 of the HCV Care & Guidance e-Handbook, Cheryl D. Levine, PhD, FNP, reviews the incidence of anemia, as well as neutropenia and thrombocytopenia, in the new triple-therapy regimens and highlights key preventive and management strategies.
Go to Activity
top
 


Chapter 2 - What You Need to Know About the New Direct-Acting Antiviral (DAA) Regimens

What do you need to know in order to start your patients with chronic HCV infection on one of the new direct-acting antiviral regimens? In this learning activity, Tiffany A. Taskaya, PA-C, CCRC, highlights what you most need to know about dosing and administration, adherence, side effects, drug interactions, contraception requirements, and more. —What You Need to Know About the New Direct-Acting Antiviral (DAA) Regimens—is the second chapter in the e-Handbook in the HCV Care and Guidance: Practical Education and Resources for Nurse Practitioners and Physician Assistants program.
Go to Activity
top
 


Chapter 1 - Getting Ready for Direct-Acting Antiviral (DAA) Therapy

Protease inhibitors boceprevir and telaprevir were approved by the FDA in May 2011 for the treatment of chronic hepatitis C, when used in combination with peginterferon and ribavirin. These approvals mark the availability of the first new anti-HCV therapies since peginterferons in combination with ribavirin were approved a decade ago. Direct-acting antiviral (DAA) therapy offers patients with genotype-1 infection a significantly greater likelihood of achieving sustained virologic response and with shorter durations of therapy. In this continuing education activity, Sherilyn C. Brinkley, MSN, CRNP, guides you through what you need to know to implement DAA therapy in your clinical practice. This is the first chapter in the e-Handbook in the HCV Care and Guidance: Practical Education and Resources for Nurse Practitioners and Physician Assistants program.
Go to Activity
top
 

 
 
CME INFORMATION

ACTIVITY GOAL
The goal of this activity is to address the needs of nurse practitioners and physician assistants for information and practical instruction regarding new direct-acting antiviral (DAA) therapies for hepatitis C and their integration into clinical practice.
  

TARGET AUDIENCE
This CME/CE activity has been designed for nurses, nurse practitioners, physician assistants, hepatologists, gastroenterologists, infectious disease specialists, and pharmacists involved in the care of patients with HCV or those at risk of acquiring the infection.
  
top2037
 
 
Projects In Knowledge®

Peer Reviewed

Vertex Pharmaceuticals Incorporated and Merck Co


EDITORIAL BOARD

CONTRIBUTING EDITOR
Sherilyn C. Brinkley, MSN, CRNP
Sherilyn C. Brinkley, MSN, CRNP
Nurse Practitioner/ Program Manager
Infectious Disease Department
Johns Hopkins University
Baltimore, Maryland
 
CONTRIBUTING EDITOR
Jill Y. Chang, PA-C
Jill Y. Chang, PA-C
Physician Assistant
Division of Gastroenterology/Hepatology
Scripps Clinic Torrey Pines
La Jolla, California
 
CONTRIBUTING EDITOR
Cheryl D. Levine, PhD, FNP
Cheryl D. Levine, PhD, FNP
Clinical Research Director
Texas Clinical Research Institute
Arlington, Texas
 
CONTRIBUTING EDITOR
Tiffany A. Taskaya, PA-C, CCRC
Tiffany A. Taskaya, PA-C, CCRC
Physician Assistant
Department of Hepatology
Beth Israel Deaconess Medical Center
Boston, Massachusetts
 
 
Copyright © 1997-2017, Projects In Knowledge, Inc. All rights reserved.
PROJECTS IN KNOWLEDGE and LIVING MEDICAL ETEXTBOOK are registered trademarks of Projects In Knowledge, Inc.
PROJECTS IN KNOWLEDGE • 290 W. Mt. Pleasant Avenue, Suite 2350 • Livingston, New Jersey 07039 (973) 890-8988






stringtrue
stringhttp://itunes.apple.com/gb/app/hcv-care-guidance-hepatitis/id461838768?mt=8